Certuity LLC Acquires New Shares in Edwards Lifesciences Co. (NYSE:EW)

Certuity LLC acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,128 shares of the medical research company’s stock, valued at approximately $232,000.

Several other large investors have also added to or reduced their stakes in EW. Alpha Financial Partners LLC purchased a new position in Edwards Lifesciences during the third quarter valued at approximately $693,000. Vontobel Holding Ltd. boosted its holdings in Edwards Lifesciences by 5.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company’s stock valued at $28,977,000 after purchasing an additional 23,560 shares during the period. nVerses Capital LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $792,000. Trust Co. of Vermont increased its holdings in shares of Edwards Lifesciences by 36.1% in the third quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock worth $199,000 after purchasing an additional 801 shares during the period. Finally, V Square Quantitative Management LLC raised its position in shares of Edwards Lifesciences by 10.6% in the third quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company’s stock worth $992,000 after buying an additional 1,437 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,750 shares of company stock valued at $1,564,255. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $75.96 on Friday. The company has a market capitalization of $44.80 billion, a P/E ratio of 10.96, a PEG ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a 50 day moving average price of $72.51 and a two-hundred day moving average price of $69.36.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent analyst reports. Robert W. Baird reduced their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday. Citigroup boosted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.